About Sulfotransferase 2B1
Sulfotransferase 2B1 (SULT2B1) is a protein
from Homo sapiens identified by UniProt accession
O00204, 365 residues long.
MolForge cross-references it against 0 known binders and
61 disease associations.
Target properties
| Protein name | Sulfotransferase 2B1 |
|---|
| UniProt accession | O00204 |
|---|
| Gene | SULT2B1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 365 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (61)
Diseases linked to this target (Open Targets).
- Ichthyosis-hypotrichosis syndrome · score 0.65
- congenital non-bullous ichthyosiform erythroderma · score 0.56
- self-healing collodion baby · score 0.46
- lamellar ichthyosis · score 0.37
- autosomal recessive congenital ichthyosis · score 0.35
- genetic disorder · score 0.19
- glioblastoma multiforme · score 0.16
- alkaline phosphatase measurement · score 0.13
- esophageal squamous cell carcinoma · score 0.08
- calf circumference measurement · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-O00204-F1 | alphafold | PREDICTED | 86.69 | — |
Amino-acid sequence (365 residues)
MDGPAEPQIP GLWDTYEDDI SEISQKLPGE YFRYKGVPFP VGLYSLESIS LAENTQDVRD DDIFIITYPK SGTTWMIEII CLILKEGDPS WIRSVPIWER APWCETIVGA FSLPDQYSPR LMSSHLPIQI FTKAFFSSKA KVIYMGRNPR DVVVSLYHYS KIAGQLKDPG TPDQFLRDFL KGEVQFGSWF DHIKGWLRMK GKDNFLFITY EELQQDLQGS VERICGFLGR PLGKEALGSV VAHSTFSAMK ANTMSNYTLL PPSLLDHRRG AFLRKGVCGD WKNHFTVAQS EAFDRAYRKQ MRGMPTFPWD EDPEEDGSPD PEPSPEPEPK PSLEPNTSLE REPRPNSSPS PSPGQASETP HPRPS
Explore Sulfotransferase 2B1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets